Brenus Pharma key facts
- Developer of anti-cancer cell-based immunotherapy designed to generate allogeneic cell vaccines for solid tumors.
- Brenus Pharma’s last known valuation is $45.4M.
- It has raised $30.0M; the latest was Later Stage VC ($23.9M) in Jul 2024.
- Notable investors include Creative Destruction Lab, Bpifrance, UI Investissement, Noshaq, Crédit Agricole Centre France Développement — 11 tracked in total.
- Status: Privately Held (backing).
Who backs Brenus Pharma
11+- ·The complete investor list: 11 names
- ·Watch Brenus Pharma: the Monday email on marks, rounds and moves
Brenus Pharma funding rounds
No funding rounds for Brenus Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Brenus Pharma valuation
Brenus Pharma's last known valuation is $45.4 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Brenus Pharma investors
11 investors are on record for Brenus Pharma, including Creative Destruction Lab, Bpifrance, UI Investissement and Noshaq.
About Brenus Pharma
Developer of anti-cancer cell-based immunotherapy designed to generate allogeneic cell vaccines for solid tumors. The company platform empowers immune cells in vivo to fight cancer through two core mechanisms: mimicking cancer nature and making it visible to the immune system. The company's therapy educates the immune system to anticipate relapse mechanisms by stimulation of selected tumor cell lines, enabling oncologists to induce response during treatment with chemotherapy or radiotherapy.
- Sector
- Healthcare
- HQ
- Issoire, France
- Founded
- 2014
- Employees
- 14
- Website
- brenus-pharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Brenus Pharma’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.